Clinical Trial Update: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ME-401 in relapsed or refractory indolent non-Hodgkin lymphoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• ME-401

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Indolent B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING